Welcome to our dedicated page for Tema Oncology ETF news (Ticker: CANC), a resource for investors and traders seeking the latest updates and insights on Tema Oncology ETF stock.
The Tema Oncology ETF (CANC) news page on Stock Titan focuses on developments related to this oncology-themed exchange-traded fund and its underlying investment universe. CANC is managed by Tema ETFs and invests in oncology companies and cancer therapies, concentrating on businesses that are involved in the fight against cancer.
News about CANC often highlights its performance relative to broader benchmarks and other healthcare and biotechnology ETFs. For example, Tema has reported periods when CANC’s returns have compared favorably with the S&P 500 index and a defined universe of healthcare and biotechnology funds. Such updates help investors understand how the fund’s oncology focus has translated into performance over time.
Coverage can also include commentary from the fund’s portfolio manager, Dr. David Song, MD, PhD, CFA, who brings a background in medicine and healthcare investing. These insights may discuss why oncology is viewed by Tema as one of the largest and fastest-growing areas of innovation within healthcare, and how the fund seeks exposure to companies at the forefront of cancer research and treatment.
In addition, the news feed may reference risk disclosures and thematic context provided by Tema, such as industry concentration risk, biotechnology industry risk, and oncology-specific considerations like regulatory approvals and product safety concerns. By following CANC-related news, investors can track how these factors intersect with fund performance and positioning.
Bookmark this page to access a centralized stream of press releases and updates tied to the Tema Oncology ETF, its strategy, and the broader oncology investment theme.
Tema Oncology ETF (CANC) surpassed $100 million in assets under management two years after launch and is described as the only pure‑play oncology ETF. The fund is up 48.0% year‑to‑date in 2025 versus the S&P 500's +15.7%, placing CANC among the top 3 performers within Bloomberg's 47 healthcare and biotech ETF universe. CANC is managed by Dr. David Song MD, PhD, CFA, who has two decades of healthcare investing experience. The announcement notes oncology's rising need and characterizes oncology investing as inherently complex and risky.